SciELO - Scientific Electronic Library Online

 
vol.140 número6Conducta suicida en niños y adolescentes ingresados en un hospital general: Análisis descriptivoSchwannoma retroperitoneal: Caso clínico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

MARTINS, Sandro José; MODESTO DOS SANTOS, Vitorino; THOMMEN TELES, Ludmila  y  ALVES LEITE, Viviane. Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab. Rev. méd. Chile [online]. 2012, vol.140, n.6, pp. 763-766. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872012000600010.

Background: We report a 54-year-old woman with an stage IIA (T2N0M0) RE and RP negative and HER2-positive ductal invasive breast cancer who developed a reversible cardiotoxicity associated with chemotherapy. After surgery, she received four cycles of doxorubicin and cyclophosfamide. Later, she used paclitaxel and trastuzumab. At the 7th cycle of trastuzumab, she had symptoms of heart failure with left ventricle ejection fraction = 59%. Trastuzumab dosage was reduced in 25%, and heart function progressively improved. Two years after her discharge, the patient remains asymptomatic. Systolic function of the left ventricle was normal before the initial dosis of trastuzumab, but significantly worsened following the beginning of drug administration. Moreover, a clear improvement of heart function was observed soon after the daily dose of trastuzumab was reduced. Better knowledge of risk factors for cardiotoxicity related to chemotherapy, and longstanding surveillance with serial echocardiograms can avoid more severe cardiotoxicity by chemotherapy.

Palabras llave : Breast neoplasms; Chemotherapy, adjuvant; drug toxicity; stroke volume; trastuzumab.

        · resumen en Español     · texto en Inglés     · pdf en Inglés